Last $30.82 USD
Change Today +1.00 / 3.35%
Volume 245.8K
FLDM On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

fluidigm corp (FLDM) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - $49.46
52 Week Low
07/12/13 - $16.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FLUIDIGM CORP (FLDM)

Related News

No related news articles were found.

fluidigm corp (FLDM) Related Businessweek News

No Related Businessweek News Found

fluidigm corp (FLDM) Details

Fluidigm Corporation develops, manufactures, and sells microfluidic systems worldwide. It offers BioMark HD System that performs high-throughput and single-cell targeted gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm Dynamic Array and Digital Array integrated fluidic circuits (IFCs). The company also provides C1 Single-Cell Auto Prep System, which enables the isolation, processing, and profiling of individual cells for genomic analysis for applications comprising single-cell targeted gene expression, single-cell micro ribonucleic acid (RNA) analysis, single-cell messenger RNA analysis, and single-cell targeted DNA sequencing using the company’s C1 Single-Cell Auto Prep Array IFCs and C1 reagent kit. In addition, it offers EP1 System, which performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays, and Fluidigm Dynamic Array and Digital Array IFCs; and Access Array System to enable PCR-based target enrichment, barcoding, and the tagging of targeted resequencing libraries. Further, the company provides Dynamic Array, Digital Array, C1 Single-Cell Auto Prep Array, and Access Array IFCs; DELTAgene and SNPtype assays; and Access Array Target-Specific primers. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies in single-cell genomics, applied genotyping, and sample preparation for targeted re sequencing markets. Fluidigm Corporation distributes its products through support organizations, distributors, or sales agents, as well as through its direct sales force. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

325 Employees
Last Reported Date: 03/12/14
Founded in 1999

fluidigm corp (FLDM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $311.6K
Chief Operating Officer
Total Annual Compensation: $296.8K
Executive Vice President of Legal Affairs, Ge...
Total Annual Compensation: $312.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $308.1K
Compensation as of Fiscal Year 2013.

fluidigm corp (FLDM) Key Developments

Fluidigm Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for 2014

Fluidigm Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. Total revenue for the first quarter of 2014 was $25.7 million, an increase of 77% from $14.5 million in the first quarter of 2013. Organic revenue (excluding revenue attributable to the CyTOF(R) 2 system and proteomics analytical consumables) was $22.9 million, an increase of 58% over the same quarter in 2013. Net loss for the first quarter of 2014 was $15.4 million, compared to a net loss of $3.6 million in the first quarter of 2013. Non-GAAP net income for the first quarter of 2014 was approximately $0.08 million, compared with $3.5 million non-GAAP net loss for the first quarter of 2013. Loss from operations was $16,579,000 against $5,067,000 a year ago. Loss before income taxes was $17,557,000 against $3,513,000 a year ago. Net loss per share, basic and diluted was $0.57 against $0.14 a year ago. Net cash used in operating activities was $10,547,000 against $884,000 a year ago. Purchases of property and equipment was $1,813,000 against $698,000 a year ago. Fluidigm is projecting 2014 total revenue to be between $111 million to $116 million. Organic revenue is now projected to be between $91 million and $94 million, an increase of 28% to 32% over 2013, versus prior growth guidance of 23% to 28%. It expects $4 million for depreciation and amortization expense. Interest expense is projected to be $5.3 million and capital spending is expected to be between $11 million and $13 million.

Fluidigm Corporation to Report Q1, 2014 Results on May 05, 2014

Fluidigm Corporation announced that they will report Q1, 2014 results at 5:00 PM, Eastern Standard Time on May 05, 2014

Fluidigm Corporation, Q1 2014 Earnings Call, May 05, 2014

Fluidigm Corporation, Q1 2014 Earnings Call, May 05, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLDM:US $30.82 USD +1.00

FLDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr11.15 SEK -0.05
Luminex Corp $16.81 USD +0.62
NanoString Technologies Inc $13.49 USD +0.13
Pacific Biosciences of California Inc $5.75 USD +0.01
Sequenom Inc $3.80 USD +0.025
View Industry Companies

Industry Analysis


Industry Average

Valuation FLDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.7x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUIDIGM CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at